Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Rises By 212.5%

Avenue Therapeutics, Inc. (NASDAQ:ATXIGet Rating) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 82,800 shares, a growth of 212.5% from the April 15th total of 26,500 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily volume of 4,880,000 shares, the short-interest ratio is presently 0.0 days.

Several institutional investors and hedge funds have recently bought and sold shares of ATXI. Citadel Advisors LLC acquired a new stake in shares of Avenue Therapeutics during the third quarter worth about $41,000. Goldman Sachs Group Inc. increased its position in shares of Avenue Therapeutics by 34.1% during the second quarter. Goldman Sachs Group Inc. now owns 23,224 shares of the company’s stock worth $58,000 after purchasing an additional 5,905 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Avenue Therapeutics by 50.8% during the third quarter. Renaissance Technologies LLC now owns 118,100 shares of the company’s stock worth $176,000 after purchasing an additional 39,786 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Avenue Therapeutics during the second quarter worth about $183,000. Institutional investors and hedge funds own 10.87% of the company’s stock.

ATXI opened at $0.32 on Thursday. The business’s 50-day simple moving average is $0.52 and its 200-day simple moving average is $0.82. Avenue Therapeutics has a one year low of $0.20 and a one year high of $5.19.

About Avenue Therapeutics (Get Rating)

Avenue Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain.

Featured Stories

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.